MSI

Content Outline

Microsatellite Instability in Cancer

Prognostic Impact of Microsatellite Instability in CRC

KEYNOTE-016 Emergence of MSI Status as a Predictive Biomarker

Methods to Test for Microsatellite Instability

Patient Case Colorectal Cancer

Optimal Treatment Selection for mCRC Depends on Molecular Testing

Evolving Society Guidelines on Molecular Testing

KEYNOTE-164 Data

Contrasting Pembrolizumab With Standard Later-Line Therapies

KEYNOTE-028 Can PD-L1 Predict Responses to PD-1 Therapy?

CheckMate-142 What Is the Optimal Immunotherapy Approach for MSI-H CRC?

CheckMate 142 Single-Agent Nivolumab in MSI-H CRC

CheckMate-142 Nivolumab-Ipilimumab Combination Results

Single-Agent or Combination Immunotherapy?

Does It Matter Whether MSI-H Status Is Germline or Somatic?

First-Line Immunotherapy for CRC on the Horizon

Patient Case #2 Gastric Cancer

Gastric Cancer Differs From Colorectal Cancer in Terms of Immunotherapy Response

KEYNOTE-059 Cohort 1 A Role for PD-1 Inhibition in Previously Treated Gastric Cancer

KEYNOTE-061 Pembrolizumab in Gastric/GEJ Cancer — Randomized Trial

KEYNOTE-062 Adding Pembrolizumab to Chemotherapy for Previously Treated Gastric/GEJ Cancer

PD-L1 May Not Be a Binary Biomarker

CheckMate-032 Combination Immunotherapy for Advanced Gastric Cancer

MSI Status as a Universal Biomarker Across Solid Tumors

Key Takeaways

Abbreviations

Abbreviations (cont)

Abbreviations (cont)